The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Sarcoma MORE >>

The FDA has granted a breakthrough therapy designation to the investigational agent selumetinib for the treatment of pediatric patients ≥3 years old with symptomatic and/or progressive, inoperable neurofibromatosis type 1

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.